SCHEMBL8720869

SCHEMBL8720869

O=C(Nc1ccc2scc(C3CCC4CCCCN4CC3)c2c1)OC1CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.39
BCHE P06276 2/20 0.39
HRH3 Q9Y5N1 7/20 0.38
FAAH O00519 1/20 0.36
MGLL Q99685 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYSLTR2 Q9NS75 1/20 0.36
CYSLTR1 Q9Y271 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SHMT2 P34897 1/20 0.36
CYP3A4 P08684 2/20 0.35
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35
HTR1D P28221 2/20 0.35
HTR1B P28222 2/20 0.35
HTR1A P08908 1/20 0.35
HTR1F P30939 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8725999 0.85 CHRNA7 (0.42) HRH3SHMT2
SCHEMBL8723856 0.84 HTR1D (0.50) HRH3NPC1RAB9AHTR1DHTR1B
SCHEMBL8725928 0.83 RORC (0.47) HRH3MEN1KMT2ANPC1RAB9A
SCHEMBL8721866 0.83 TP53 (0.38) HRH3KMT2ANPC1RAB9ASHMT2
SCHEMBL8721249 0.83 ALPL (0.41) HRH3KMT2APOLB
SCHEMBL8721062 0.83 LMNA (0.43) HRH3MEN1KMT2ANPC1RAB9A
SCHEMBL8723972 0.82 HRH3 (0.35) HRH3MEN1KMT2ASHMT2HTR1D
SCHEMBL8724094 0.82 ACKR3 (0.39) HRH3KMT2ANPC1RAB9AHTR1D
SCHEMBL8721795 0.82 KMT2A (0.46) HRH3MEN1KMT2ANPC1RAB9A
SCHEMBL8721868 0.82 HRH3 (0.34) HRH3SHMT2MAPTHTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D ACHE 4406/4885BCHE 4303/4885HRH3 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.